Mr Nowers joins Cell Medica from the cancer immunotherapy company Kite Pharma, where he was Head of Europe and responsible for the full commercialisation of the CAR-T therapy axicabtagene ciloleucel.

Previous to his role at Kite, he has had a career spanning more than 25 years in the biopharma industry. He has held a number of senior leadership roles that included CEO of Avantogen Oncology, General Management roles at Amgen, and senior global and regional commercial leadership roles at Bristol-Myers Squibb (BMS).

“Cell Medica has an exciting array of technologies that will help unlock the potential of personalised cellular immunotherapies for both blood cancers and solid tumours. I look forward to working with the Company’s talented executive and scientific teams to take these promising treatments to patients through clinical development,” Chris Nowers commented.